{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:47:37Z","timestamp":1767707257548,"version":"3.41.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Russian state budget project to the ICBFM SB RAS","award":["121030200173-6","121030200173-6","121030200173-6","121030200173-6"],"award-info":[{"award-number":["121030200173-6","121030200173-6","121030200173-6","121030200173-6"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02730-4","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T04:25:26Z","timestamp":1745814326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The influence of maximal androgen blockade and radical prostatectomy on urinary extracellular vesicle miRNA expression"],"prefix":"10.1007","volume":"42","author":[{"given":"E. V.","family":"Shutko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O. E.","family":"Bryzgunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. A.","family":"Ostaltsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. P.","family":"Laktionov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Y.","family":"Konoshenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"2730_CR1","first-page":"188625","volume":"2","author":"MY Konoshenko","year":"1876","unstructured":"Konoshenko MY, Bryzgunova OE, Laktionov PP. (2021) miRNAs and androgen deprivation therapy for prostate cancer. Biochim Biophys Acta Rev Cancer. 1876;2:188625.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2730_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2490-11-7","volume":"11","author":"N Fujimoto","year":"2011","unstructured":"Fujimoto N, Kubo T, Shinsaka H, Matsumoto M, Shimajiri S, Matsumoto T. Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer. BMC Urol. 2011;11:7.","journal-title":"BMC Urol"},{"key":"2730_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01761-1","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhao J, Ding M, et al. Loss of exosomal miR-146a-5p from cancer-associated fibroblasts after androgen deprivation therapy contributes to prostate cancer metastasis. J Exp Clin Cancer Res. 2020. https:\/\/doi.org\/10.1186\/s13046-020-01761-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"2730_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374.","journal-title":"JAMA"},{"issue":"12","key":"2730_CR5","doi-asserted-by":"publisher","first-page":"4088","DOI":"10.3390\/ijms19124088","volume":"19","author":"EA Lekchnov","year":"2018","unstructured":"Lekchnov EA, Amelina EV, Bryzgunova OE, et al. Searching for the novel specific predictors of prostate cancer in urine: the analysis of 84 miRNA expression. Int J Mol Sci. 2018;19(12):4088.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2730_CR6","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3390\/diagnostics10080600","volume":"10","author":"MY Konoshenko","year":"2020","unstructured":"Konoshenko MY, Bryzgunova OE, Lekchnov EA, et al. The Influence of radical prostatectomy on the expression of cell-free miRNA. Diagnostics (Basel). 2020;10(8):600.","journal-title":"Diagnostics (Basel)"},{"key":"2730_CR7","first-page":"0014","volume":"3","author":"O Bryzgunova","year":"2024","unstructured":"Bryzgunova O, Yakovlev A, Ostaltsev I, Laktionov P, Konoshenko M. MiRNA expression in plasma extracellular vesicles of prostate cancer patients after radical prostatectomy. ExRNA. 2024;3:0014.","journal-title":"ExRNA"},{"issue":"6","key":"2730_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2217\/epi-2019-0275","volume":"12","author":"I Abramovic","year":"2020","unstructured":"Abramovic I, Ulamec M, Katusic Bojanac A, Bulic-Jakus F, Jezek D, Sincic N. miRNA in prostate cancer: challenges toward translation. Epigenomics. 2020;12(6):543\u201358.","journal-title":"Epigenomics"},{"issue":"11","key":"2730_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s12094-012-0877-0","volume":"14","author":"I Casanova-Salas","year":"2012","unstructured":"Casanova-Salas I, Rubio-Briones J, Fern\u00e1ndez-Serra A, et al. miRNAs as biomarkers in prostate cancer. Clin Transl Oncol. 2012;14(11):803\u201311.","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"2730_CR10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1515\/cclm-2015-1073","volume":"55","author":"X Filella","year":"2017","unstructured":"Filella X, Foj L. miRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017;55(5):715\u201336.","journal-title":"Clin Chem Lab Med"},{"issue":"4","key":"2730_CR11","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/andr.12994","volume":"9","author":"MY Konoshenko","year":"2021","unstructured":"Konoshenko MY, Laktionov PP. MiRNAs and radical prostatectomy: current data, bioinformatic analysis and utility as predictors of tumour relapse. Andrology. 2021;9(4):1092\u2013107.","journal-title":"Andrology"},{"issue":"10","key":"2730_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2174\/1568009618666180315160125","volume":"18","author":"A Razdan","year":"2018","unstructured":"Razdan A, de Souza P, Roberts TL. Role of MicroRNAs in treatment response in prostate cancer. Curr Cancer Drug Targets. 2018;18(10):929\u201344.","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"2730_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/fon-2022-0891","volume":"19","author":"JR Vazquez-Urrutia","year":"2023","unstructured":"Vazquez-Urrutia JR, Torres-Bustamante MI, Cerda-Cruz CR, Bravo-Cuellar A, Ortiz-Lazareno PC. The role of miRNA in prostate cancer diagnosis, prognosis and treatment response: a narrative review. Future Oncol. 2023;19(1):77\u201393.","journal-title":"Future Oncol"},{"issue":"12","key":"2730_CR14","first-page":"1379","volume":"30","author":"PA Patil","year":"2015","unstructured":"Patil PA, Magi-Galluzzi C. MicroRNA in prostate cancer: Practical aspects. Histol Histopathol. 2015;30(12):1379\u201396.","journal-title":"Histol Histopathol"},{"issue":"15","key":"2730_CR15","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1038\/onc.2010.59","volume":"29","author":"ME Peter","year":"2010","unstructured":"Peter ME. Targeting of mRNAs by multiple miRNAs: the next step. Oncogene. 2010;29(15):2161\u20134.","journal-title":"Oncogene"},{"issue":"3","key":"2730_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/diagnostics11030384","volume":"11","author":"MY Konoshenko","year":"2021","unstructured":"Konoshenko MY, Lekchnov EA, Bryzgunova OE, et al. Isolation of extracellular vesicles from biological fluids via the aggregation-precipitation approach for downstream miRNAs detection. Diagnostics (Basel). 2021;11(3):384.","journal-title":"Diagnostics (Basel)"},{"key":"2730_CR17","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ab.2016.01.025","volume":"499","author":"EA Lekchnov","year":"2016","unstructured":"Lekchnov EA, Zaporozhchenko IA, Morozkin ES, et al. Protocol for miRNA isolation from biofluids. Anal Biochem. 2016;499:78\u201384.","journal-title":"Anal Biochem"},{"issue":"9","key":"2730_CR18","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1073\/pnas.1100048108","volume":"108","author":"M Boeri","year":"2011","unstructured":"Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011;108(9):3713\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2730_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12859-015-0820-9","volume":"16","author":"E Landoni","year":"2015","unstructured":"Landoni E, Miceli R, Callari M, et al. Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. BMC Bioinformatics. 2015;16:388.","journal-title":"BMC Bioinformatics"},{"issue":"7","key":"2730_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.2174\/138920210793175895","volume":"11","author":"LA Macfarlane","year":"2010","unstructured":"Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537\u201361.","journal-title":"Curr Genomics"},{"key":"2730_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6524-3_1","volume":"1509","author":"A Vishnoi","year":"2017","unstructured":"Vishnoi A, Rani S. MiRNA biogenesis and regulation of diseases: an overview. Methods Mol Biol. 2017;1509:1\u201310.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2730_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.2174\/1568009617666170630142725","volume":"18","author":"A Tiwari","year":"2018","unstructured":"Tiwari A, Mukherjee B, Dixit M. MicroRNA key to angiogenesis regulation: miRNA biology and therapy. Curr Cancer Drug Targets. 2018;18(3):266\u201377.","journal-title":"Curr Cancer Drug Targets"},{"issue":"11","key":"2730_CR23","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1111\/cas.15948","volume":"114","author":"W Wang","year":"2023","unstructured":"Wang W, Kong P, Feng K, et al. Exosomal miR-222-3p contributes to castration-resistant prostate cancer by activating mTOR signaling. Cancer Sci. 2023;114(11):4252\u201369.","journal-title":"Cancer Sci"},{"key":"2730_CR24","doi-asserted-by":"publisher","first-page":"153303382198981","DOI":"10.1177\/1533033821989817","volume":"20","author":"XB Sun","year":"2021","unstructured":"Sun XB, Chen YW, Yao QS, et al. MicroRNA-144 suppresses prostate cancer growth and metastasis by targeting EZH2. Technol Cancer Res Treat. 2021;20:1533033821989817.","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"2730_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s10517-017-3620-6","volume":"162","author":"AI Osip'yants","year":"2017","unstructured":"Osip\u2019yants AI, Knyazev EN, Galatenko AV, et al. Changes in the level of circulating hsa-miR-297 and hsa-miR-19b-3p miRNA are associated with generalization of prostate cancer. Bull Exp Biol Med. 2017;162(3):379\u201382.","journal-title":"Bull Exp Biol Med"},{"issue":"5","key":"2730_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/pros.21270","volume":"71","author":"XB Shi","year":"2011","unstructured":"Shi XB, Xue L, Ma AH, et al. miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate. 2011;71(5):538\u201349.","journal-title":"Prostate"},{"issue":"16","key":"2730_CR27","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1002\/1878-0261.13255","volume":"16","author":"K Ganapathy","year":"2022","unstructured":"Ganapathy K, Ngo C, Andl T, Coppola D, Park J, Chakrabarti R. Anticancer function of microRNA-30e is mediated by negative regulation of HELLPAR, a noncoding macroRNA, and genes involved in ubiquitination and cell cycle progression in prostate cancer. Mol Oncol. 2022;16(16):2936\u201358.","journal-title":"Mol Oncol"},{"issue":"8","key":"2730_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/cancers9080102","volume":"9","author":"KI Takayama","year":"2017","unstructured":"Takayama KI, Misawa A, Inoue S. Significance of microRNAs in androgen signaling and prostate cancer progression. Cancers (Basel). 2017;9(8):102.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2730_CR29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12038-019-9920-4","volume":"44","author":"S Liu","year":"2019","unstructured":"Liu S, Wang Q, Liu Y, Xia ZY. miR-425-5p suppresses tumorigenesis and DDP resistance in human-prostate cancer by targeting GSK3\u03b2 and inactivating the Wnt\/\u03b2-catenin signaling pathway. J Biosci. 2019;44(4):102.","journal-title":"J Biosci"},{"key":"2730_CR30","doi-asserted-by":"publisher","first-page":"945057","DOI":"10.3389\/fonc.2022.945057","volume":"12","author":"S Choi","year":"2022","unstructured":"Choi S, Lee S, Han YH, et al. miR-31-3p functions as a tumor suppressor by directly targeting GABBR2 in prostate cancer. Front Oncol. 2022;12:945057.","journal-title":"Front Oncol"},{"key":"2730_CR31","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/j.omtn.2022.02.005","volume":"27","author":"MT Di Martino","year":"2022","unstructured":"Di Martino MT, Arbitrio M, Caracciolo D, et al. miR-221\/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: a systematic review. Mol Ther Nucleic Acids. 2022;27:1191\u2013224.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"8","key":"2730_CR32","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1038\/s12276-022-00837-6","volume":"54","author":"J Gan","year":"2022","unstructured":"Gan J, Liu S, Zhang Y, et al. MicroRNA-375 is a therapeutic target for castration-resistant prostate cancer through the PTPN4\/STAT3 axis. Exp Mol Med. 2022;54(8):1290\u2013305.","journal-title":"Exp Mol Med"},{"issue":"40","key":"2730_CR33","doi-asserted-by":"publisher","first-page":"67626","DOI":"10.18632\/oncotarget.18795","volume":"8","author":"SM Egan","year":"2017","unstructured":"Egan SM, Karasik E, Ellis L, Gollnick SO. miR-30e* is overexpressed in prostate cancer and promotes NF-\u03baB-mediated proliferation and tumor growth. Oncotarget. 2017;8(40):67626\u201338.","journal-title":"Oncotarget"},{"issue":"11","key":"2730_CR34","doi-asserted-by":"publisher","first-page":"371.e19","DOI":"10.1016\/j.urolonc.2024.06.017","volume":"42","author":"EV Shutko","year":"2024","unstructured":"Shutko EV, Bryzgunova OE, Murina EA, et al. Influence of radical prostatectomy on miRNA dynamics in urine extracellular vesicles. Urol Oncol. 2024;42(11):371.e19-30.","journal-title":"Urol Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02730-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02730-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02730-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T03:15:53Z","timestamp":1748661353000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02730-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2730"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02730-4","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses or interpretation of data; and in the writing of the manuscript or in the decision to publish the results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the ethics committee of ICBFM SB RAS (No. 10, 22.12.2008).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"185"}}